Norgine rolls out ANGUSTA in the UK for oral induction of labor

The need for induced labor becomes necessary under circumstances where the risk of fetal or maternal health outweighs the wait for impulsive labor

UK-based pharmaceutical company- Norgine has recently announced rolling out ANGUSTA (misoprostol) in the country for oral induction of labor. Reports have it that the drug would now offer an oral treatment option for the induction of labor in line with the currently available vaginally administered methods.

As per credible reports, the efficiency and safety of misoprostol 25 micrograms has been assessed using both dosing regimens and an expansive range of studies including a compassionate use program, which demonstrate the common side effects such as vomiting, postpartum haemorrhage, nausea, and meconium stain.

The need for induced labor becomes necessary under circumstances where the risk of fetal or maternal health outweighs the wait for impulsive labor, generating humongous demand for ANGUSTA.

Misoprostol, an active substance in ANGUSTA, is deemed to be synthetic analogue of PGE1, a naturally extracted compound. It has been reported that physiologically, the drug has been shown to augment mammalian collagenase activity, causing uterine contractions and cervical ripening.

Moreover, according to official sources, misoprostol 25 micrograms is anticipated to be directed by trained obstetric staff in a healthcare setting where facilities for constant uterine and fetal monitoring is feasible.

It would be essential to note that Norgine had implemented ANGUSTA into its portfolio post its latest acquisition of Azanta, which has bolstered Norgine’s position as a leading European specialist pharmaceutical firm.

Commenting on the recent launch, General Manager of Norgine in the United Kingdom- Andy Crichton stated that their organization is extremely pleased to be delivering women and healthcare experts an oral treatment option induction of labor in the UK, a treatment that is required to support women, midwives, and obstetricians.

Source Credit: https://www.prnewswire.co.uk/news-releases/norgine-uk-launches-angusta-r-misoprostol-in-the-uk-for-oral-induction-of-labour-845349494.html